Loading...
Date of Award
Spring 2025
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Diana Hawthorne
Abstract
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition marked by painful nodules, abscesses, and scarring in intertriginous areas. Its physical and psychosocial impacts are significant, yet delayed diagnosis and suboptimal treatment remain common due to its complex, not fully understood pathogenesis. As HS progresses through Hurley stages I–III, it becomes increasingly resistant to treatment and poses higher risks of serious complications such as infection, sepsis, and malignant transformation. This presentation emphasizes the critical role of early recognition and appropriate, stage-based management to improve patient outcomes and quality of life. Drawing on current evidence-based guidelines, it explores the multifactorial etiology of HS—including autoinflammatory, hormonal, and microbial components—and outlines treatment options ranging from topical agents to systemic therapies and biologics. The talk also addresses the gaps in provider knowledge, the need for multidisciplinary care, and the urgent demand for continued research. Ultimately, the goal is to equip clinicians with the awareness and tools necessary to intervene early and prevent irreversible disease progression in HS patients.
Recommended Citation
Carlson, Mia, "The Importance of Early Diagnosis & Treatment of HS in Attempt to Prevent Disease Progression" (2025). Capstone Showcase. 17.
https://scholarworks.arcadia.edu/showcase/2025/pa/17
The Importance of Early Diagnosis & Treatment of HS in Attempt to Prevent Disease Progression
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition marked by painful nodules, abscesses, and scarring in intertriginous areas. Its physical and psychosocial impacts are significant, yet delayed diagnosis and suboptimal treatment remain common due to its complex, not fully understood pathogenesis. As HS progresses through Hurley stages I–III, it becomes increasingly resistant to treatment and poses higher risks of serious complications such as infection, sepsis, and malignant transformation. This presentation emphasizes the critical role of early recognition and appropriate, stage-based management to improve patient outcomes and quality of life. Drawing on current evidence-based guidelines, it explores the multifactorial etiology of HS—including autoinflammatory, hormonal, and microbial components—and outlines treatment options ranging from topical agents to systemic therapies and biologics. The talk also addresses the gaps in provider knowledge, the need for multidisciplinary care, and the urgent demand for continued research. Ultimately, the goal is to equip clinicians with the awareness and tools necessary to intervene early and prevent irreversible disease progression in HS patients.